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1. Introduction 
It is known that General Anxiety Disorder (GAD), falling into the category of anxiety 
disorders with symptoms of anxiety, worry and apparent alertness, displays a fairly 
constant prevalence in the general population. Its lifelong prevalence in the general 
population is 5% according to the criteria of DSM and 6.5% according to broader criteria 
of ICD-10. 
Among anxiety disorders, GAD patients often consult primary care physicians (PCPs) for 
their treatment. An international study conducted by the World Health Organization 
(WHO) found the frequency of GAD in primary health care at 14.9%, 3.7% and 0.9% in 
Greece, Italy and Turkey respectively. Despite these different figures among countries 
which are thought to emerge from structural differences of primary health care services, it 
was found out that the point prevalence of GAD in primary care was much higher (7.9%) 
than that of the general population. Through reanalysis of WHO's data, it was also shown 
that 25% of these patients have pure GAD without any comorbidity. In light of this data, it 
can be concluded that GAD is the most frequent mental disorder after depression in primary 
care, and that patients favour primary health care services for their treatment. 
The comorbidity of GAD patients with other psychiatric disorders brings about an increase 
in the frequency of the health care system use, with longer periods of hospitalization, more 
frequent use of diagnostic tests and medication, and therefore, a heavy financial burden.  
This, in turn, implies more serious family problems and prolonged absence from work. 
There is abundant evidence showing that GAD decreases the quality of life considerably 
due to invalidity and disability. 
It is reported that patients complain of physical symptoms more often than psychological, 
and worry is cited as the main problem for only 13% of GAD patients in primary care. The 
patients with GAD mostly consult primary care for aches, sleep problems and somatic 
problems. Somatic complaints of patients usually appear in the form of chronic medical 
conditions such as chest pain, chronic fatigue syndrome, irritable bowel syndrome and 
hypertension, diabetes and cardiac diseases. This is an important factor that complicates the 
accurate diagnosis of patients and also delays their treatment. The period between the time 
when the first symptoms of GAD appear and the time of the patient's consultation with the 
family physician or its equivalent can last for up to one year. Furthermore, it can take as 
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long as seven years for the first consultation with the expert at an anxiety clinic. It was 
observed that about one third of GAD patients were not given a proper psychological 
diagnosis by family physicians. 
Stigmatization is an important factor in insufficient diagnosis and this can account for 
why a significant number of patients do not express their emotional problems to their 
physicians. Patients with GAD are often unsuccessful at identifying that their symptoms 
as related to psychological disorders. People who minimize and normalize their 
symptoms are mostly young male patients and it is reported that they receive fewer 
correct diagnoses. 
Along all these patient-related factors, it is clear that there are huge discrepancies in 
physicians’ diagnostic skills, emerging from their knowledge, abilities and approaches. 
Longer consultation periods do not increase chance of correct diagnosis of diseases either. 
However, while empathy, interest in psychiatry and asking questions about family and 
domestic problems can increase the chance for an accurate diagnosis, coexisting organic 
diseases complicate it further. In a study conducted over a group of patients who mostly 
rely on using primary care services, GAD was found to be the disease which was most 
difficult to diagnose and caused most frustration for the physicians. It could be argued that 
this seriously affects physicians’ skills to diagnose and treat their patients appropriately. It is 
apparent that physicians require tools to use for diagnosis. 
The low rate of recognition and diagnosis of GAD in primary care presents a barrier for 
appropriate treatment and referrals needed for it. However, primary care physicians are the 
group with access to the largest body of patients. 
The problems encountered in primary care diagnosis and management of anxiety in GAD 
are multifaceted and multiphase, which complicates the solutions as well. First of all, social 
interventions, including education campaigns which would improve society's approach to 
mental problems and decrease stigmatization, are required. Furthermore, increasing 
awareness of primary care physicians and equipping them with proper scanning tools is a 
necessity. Finally, developing national diagnosis and treatment guidelines, and promoting 
evidence based medical practice is also of great importance. 
2. Epidemiology of GAD 
Before the 1980s, Generalized Anxiety Disorder (GAD) was labelled as ‘anxiety neurosis’ 
characterized by excessive worrying and marked symptoms of hypervigilence and 
anxiety. GAD was first conceptualized in the Diagnostic and Statistical Manuel of Mental 
Disorders-III (DSM) in 1980 and its diagnostic criteria have changed since then. The 
current criteria in DSM-IV (Table 1) and the International Classification of Diseases-10 
(ICD) (Table 2) for GAD differ considerably with ICD-10 listing a broader spectrum of 
symptoms. The differences in the understanding GAD between Europe and the United 
States predominantly based on the fact that ICD-10 is preferred in Europe, while DSM-IV 
is preferred in the United States (Wittchen & Hoyer, 2001; Lieb et al., 2005). These 
preferences have a substantial impact on the epidemiological results. The most likely 
lifetime prevalence for GAD in the general population is 5% (ranges between 0.8-21.7% 
with different assessment tools in different countries) with DSM criteria and slightly 
higher, 6.5%, with ICD-10 criteria (Bijl et al., 1998; Wittchen & Hoyer, 2001; Lieb et al., 
2005; Mergl et al., 2007; Serrano-Blanco et al., 2010). 
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A. Excessive anxiety and worry (apprehensive expectation), occurring more days than not 
and for at least 6 months, about  a number of events or activities (such as work or school 
performance) 
B. The person finds it difficult to control the worry 
C. The anxiety and worry are associated with three (or more) of the following six 
symptoms (with at least some symptoms present for more days than not for the past 6 
months). Note: only one item is required in children 
(1) restlessness or feeling keyed up or on edge 
(2) being easily fatigued 
(3) difficulty concentrating or mind going blank 
(4) irritability 
(5) muscle tension 
(6) sleep disturbance (difficulty falling or staying asleep, or restless unsatisfying sleep) 
D. The focus of the anxiety and worry is not confined to features of an Axis I disorder. 
E.g., the anxiety or worry is not about having a panic attack (as in panic disorder), being 
embarrassed in public (as in social phobia), being contaminated (as in obsessive 
compulsive disorder), being away from home or close relatives (as in separation anxiety 
disorder), gaining weight (as in anorexia nervosa), having multiple physical complaints 
(as in somatisation disorder), or having serious illness (as in hypochondriasis), and the 
anxiety and worry do not occur exclusively during posttraumatic stress disorder 
E. The anxiety, worry, or physical symptoms cause clinically significant distress or 
impairment in social, occupational, or other important areas of functioning. 
F. The disturbance is not due to the direct physiological effects of a substance (e.g, a drug 
of abuse, a medication) or general medical condition (e.g., hyperthyroidism) and does not 
occur exclusively during a mood disorder, a psychotic disorder or a pervasive 
developmental disorder 
Table 1. DSM-IV criteria for generalized anxiety disorder 
 
Anxiety that is generalized and persistent but not restricted to, or even strongly 
predominating in, any particular environmental circumstances (i.e. it is "free-floating"). 
The dominant symptoms are variable but include complaints of persistent nervousness, 
trembling, muscular tensions, sweating, light-headedness, palpitations, dizziness, and 
epigastric discomfort. Fears that the patient or a relative will shortly become ill or have an 
accident are often expressed. 
Anxiety: 
 neurosis 
 reaction 
 state 
Excludes: neurasthenia (F48.0) 
Table 2. ICD-10 Criteria for Generalized anxiety disorder (F41.1) 
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The data, both European and non-European, suggests that GAD is most common among 
older age groups, unlike other anxiety disorders. It also shows that the likelihood of 
diagnosis of GAD increases with age: for women after the age of 35, and for men after the 
age of 45. It is relatively rare in the first two decades of life, with lower prevalence rates 
among adolescents and young adults. However, the age of onset has a bimodal distribution- 
GAD onset occurs earlier if it is the primary presentation and later if it is secondary 
(Culpepper, 2002; Lieb et al, 2005). GAD occurs twice as often in women as men, with total 
lifetime prevalence rates of 6.6% and 3.6%, respectively (Carter et al., 2001; Allgulander, 2006). 
Other factors significantly associated with GAD are determined to be: discontinued marriage 
(separated, widowed, or divorced), unemployed or being a house-wife while urbanicity, low 
income, fewer years of education, more life difficulties, and chronic medical disorders and 
religion showed limited associations (Wittchen & Hoyer, 2001; Young et al., 2001) 
Similarly to patients that suffer of panic disorders, GAD patients often consult primary care 
physicians for their treatment. An international study conducted by the World Health 
Organization (WHO) found the frequency of GAD in primary health care at 14.9%, 3.7% and 
0.9% in Greece, Italy and Turkey respectively. Despite these different figures among 
countries which are thought to emerge from structural differences in primary health care 
services, it was found out that the point prevalence of GAD in primary care was much 
higher (7.9%) than that of the general population (Ustun & Sartorius, 1995). Through 
reanalysis of WHO's data, it was also shown that 25% of these patients have pure GAD 
without any comorbidity (Lieb et al., 2005). The GADIS study determined the prevalence of 
pure GAD at 4.1%, and all GAD at 8.3% in primary care, while Kroenke et al. found the 
prevalence of GAD in primary care to be 7.6% (Ansseau et al., 2005; Kroenke et al., 2007). In 
light of this data, it can be concluded that GAD is the most frequent mental disorder after 
depression in primary care, and that patients favour primary health care services for their 
treatment. 
3. Presentation and recognition of GAD in primary care 
GAD symptoms wax and wane over time, with exacerbations of acute anxiety to response 
stress. Many patients with GAD readily report “I’ve been a worrier all my life”. Studies 
support its episodic pattern with remission and recurrence periods evident for many years. 
(Wittchen & Hoyer, 2001; Allgulander, 2006). 
GAD is a disabling condition and a social disability as severe as chronic somatic disorders 
such as arthritis, hypertension, asthma, and diabetes (Maier et al., 2000; Wittchen & Hoyer, 
2001; Kessler et al., 2001; Roy-Byrne Wagner, 2004 ; Lieb, 2005). Wittchen et al. have shown 
that only 13% of GAD patients in primary care identify anxiety as the primary problem 
(Wittchen, 2002). Mostly, patients complain of somatic and sleeping problems (Wittchen & 
Hoyer, 2001). Accompanying symptoms include muscle tension, headache, muscle aches, 
restlessness, irritability, gastrointestinal symptoms, and difficulty in concentrating, fatigue, 
insomnia (Shearer, 2007). Patients are unlikely to directly and openly complain of anxiety 
symptoms. Cardiac and gastrointestinal symptoms of anxiety deserve special attention so as 
not to be misinterpreted in differential diagnosis and to avoid high costs of potential 
unnecessary screening for accurate diagnosis. GAD was determined to be primary diagnosis 
among 20% of patients with an atypical chest pain; 55% of patients with chest pain & normal 
coronary arteries; and 50% of patients seeking a cardiac evaluation (Roy-Byrne Wagner, 
2004). Similarly, - in patients with inflammatory bowel syndrome GAD was showed to be in 
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high prevalence (Roy-Byrne Wagner, 2004). A longitudinal study that determines the under-
recognition of mental disorders showed that 18% of patients that had severe symptoms of 
depression or anxiety according to the general health questionnaire had never received a 
diagnosis from their general practitioners (GPs) (Kessler et al., 2002).  
In another study, first three common reasons for the GP visit were listed as oto-rhino-
laryngology (ORL), cardiovascular, and rheumatologic problems. However, a psychiatric 
problem was mentioned only in 5.4% of the cases. On the other hand, for the same sample, 
the prevalence of a psychiatric disorder was found 42.5%, and GAD prevalence was 10.3%, 
detected by PRIME-MD (Ansseau et al., 2004). A different study showed that 69.6% of the 
patients reporting anxiety/depression as a reason for consulting their GP had GAD 
(Ansseau et al., 2005). 
Not only patients and primary care physicians’ factors, but also the waxing and waning 
nature of GAD, leading to a “discrepancy” between primary reasons for visiting the GPs and 
actual diagnosis is important for recognizing GAD accurately (Ansseau et al., 2004; Tylee & 
Walters, 2007).  
Chronic nature of GAD with remissions and recurrences, symptoms do not meet the criteria 
in periods of recovery between episodes and substantial overlap with other medical and 
psychological disorders may make it difficult to easily detect it (Kroenke et al., 1997, Roy-
Byrne Wagner, 2004; Allgulander, 2006). Major depressive disorder is seen in at least one-
third of primary care patients with GAD (Carter et al., 2001; Stein, 2003). Comorbidity with 
panic disorder, social phobia and specific phobia, and post-traumatic stress disorder is also 
common. Comorbidity is generally associated with increased severity and persistence of the 
disorders (Allgulander, 2006). However, GAD patients were found to be diagnosed with 
two or more comorbid disorders more often than any other disorder (Carter et al., 2001). 
Rodrigues et al. showed that primary care patients in the study population showed as much 
Axis I comorbidity as psychiatric treatment-seeking population. This is an important finding 
that questions previous assumptions about treatment-seeking in mental health settings as an 
indication of illness severity (Rodrigues et al.; 2004). 
It is known that there is a wide variation in the ability of primary care physicians to 
diagnose GAD due to differences in knowledge, skills, and attitudes. Not only factual 
knowledge but also clinical skills, particularly communication skills and interview 
techniques, are important in the management of psychiatric disorder. Other obstacles have 
been mentioned: competing demands on PCPs time to interview patients within the limit of 
typical 15-min clinical encounters, frequent somatisation of mental disorders, underlying 
comorbidity, and preoccupation of an organic disease. However, empathy, an interest in 
psychiatry and asking about family and problems at home can help with the recognition 
(Ansseau et al., 2004; Rollman et al., 2005; Allgulander, 2006; Tylee & Walters, 2007). 
Harman et al. reported that vast majority of PCPs’ diagnosis were branded “anxiety, 
unspecified”. They concluded that this may reflect that the symptoms of primary care 
patients do not fulfil a specific diagnosis like GAD, or current description of anxiety 
disorders in commonly used classifications is too complicated to be easily applied by PCPs 
(Harman et al., 2002). 
With regards to the patients, this discrepancy can be due to the considerable resistance to a 
psychiatric diagnosis and reluctance to discuss their psychiatric condition for the fear of 
stigmatization, and may account for 45% of people failing to share their emotional problems 
with their physicians (Cape & McCullech, 1999; Tylee & Walters, 2007). Another factor is 
that patients do not consider their psychiatric symptomatology as sufficiently unusual or 
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troublesome to be mentioned until the underlying anxiety is identified (Harman et al., 2002; 
Ansseau et al., 2004). Kessler et al. found different styles of symptom attribution, and 
showed that patients who attribute a psychological cause are more likely to be recognized 
when compared to patients who normalize or minimize their symptoms. Normalisers were 
determined as younger and male patients (Kessler et al., 1999). Harman et al. argued that 
reimbursement issues or concerns over a patient’s willingness to be diagnosed with an 
anxiety disorder could also be possible explanations (Harman et al., 2002). Besides these, a 
qualitative study had shown that patients were open to suggestions from their GPs or 
otherwise. Furthermore, several described their GPs as “marvellous” or “has never let me 
down”. They believed it was helpful to talk to someone about their problem; however the 
search for this person was seen as difficult. Patients expressed the need for an easier access 
to professional help, suggesting their GPs should be more active in referrals, checking up on 
the patients’ progress through phone calls, follow-up sessions, and home visits. Patients also 
expressed concern about interfering their GP’s busy schedule, because of GP’s involvement 
with more pressing medical cases. However some also conserve their hope for their GPs to 
do more than prescribe drugs, waiting for encouragement of to disclose their emotional or 
psychological problems. Another concern of theirs was the waiting time, since they wish to 
speak to someone at the moment they are feeling bad, instead of waiting for appointments 
(Kadam et al., 2001).  
Since GAD is highly prevalent in the primary care setting, patients with the disorder are 
likely to be high users of primary care health services, both in terms of the frequency of 
visits and the sheer number of patients contacting primary care providers because of 
problems associated with the disorder (Wittchen & Hoyer, 2001). Young et al. showed that 
during a 1-year period, 84.3% of individuals with an anxiety disorder only visit PCPs 
(Young et al., 2001). Harman et al. found the proportion of visits to PCPs as 46.5-48.2%, 
which still holds true today. They also reported that anxiety disorder diagnose were 
recorded more often during visits where the physician had seen the patient before, and a 
depression diagnosis had also been recorded during that same visit (Harman et al., 2002). 
Patients with pure GAD are 1.6 times more likely to have four or more visits to PCPs than 
patients without GAD or major depressive episodes (MDE) (Wittchen, 2002). Bélanger et al. 
determined that patients with positive screening for GAD reported more annual medical 
visits (5.3 versus 3.4) than other patients, and 44.5% of the positive screening group reported 
consulting a family physician five times or more yearly, compared with 20.0% in the 
negative screening group. However, they did not report consulting other resources more 
often, suggesting that patients with GAD might mostly seek treatment from PCPs (Bélanger 
et al., 2005). Kronke et al. determined the self-reported 2.9 (2.2-3.6) physician visits in the 
preceding 3 months (Kroenke et al., 2007).  
GAD patients have to be identified so they can be properly treated. Wagner et al. found that 
family physicians (FPs) diagnosed 39% of cases correctly while 29.3% left with no 
psychological diagnosis (Wagner et al., 2006).  
There is an obvious need for tools that will help PCPs in diagnosing and monitoring GAD 
patients. There are several recommended specifically for GAD, such as Generalized Anxiety 
Disorder Inventory (GADI), GAD-7; tools for severity assessment such as Hamilton Anxiety 
Scale (HAM-A); and tools for measurement of functional impairment due to anxiety such as 
Overall Anxiety Severity and Impairment Scale (OASIS). Web-based screening can also be a 
choice as being cost-efficient (Allgulander, 2009; Katzman, 2009; Roy-Byrne, 2009). Ruiz et 
al. showed that GAD-7 highly correlated not only with specific anxiety measures but also 
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with disability measures, which can be used for exploring the level of disability in GAD 
patients in primary care setting (Ruiz et al., 2011). 
In the absence of systematic screening, 30-40% of anxiety and depression patients are 
identified in primary care setting. There are studies showing evidence for and against the 
screening. Some reviews point that screening alone does not improve patient’s outcome. 
However, others concluded that screening has increased benefits when combined with 
effective treatment and follow up. A barrier for screening is that tools’ length, specificity for 
a single disorder or both. Means-Christensen et al. recommended Anxiety and Depression 
Detector (ADD) as screening instrument for anxiety and depressive disorders in primary 
care. ADD’s sensitivity and specificity ranges between 0.87-1.0 and 0.42-0.68, respectively 
(Means-Christensen et al.; 2001). Rollman et al. suggested that PRIME-MD can be used in 
identifying primary care patients with GAD as a part of broader strategy to improve quality 
of care for GAD patients (Rollman et al., 2005). 
PCPs have to use their advantage of continuous contact and communication skills for 
efficient history taking. To aid accurate diagnosis and to rule out other possible diagnosis, 
both the patient’s and the family’s histories should be assessed carefully. Recent life events 
and other health problems including depression, substance or alcohol abuse and 
dependence should be noted. Multiple visits to PCPs, consultations with different specialists 
such as gastroenterologists, and consultations that end with no definite diagnosis should be 
carefully considered (Katzman, 2009). 
4. Burden of GAD in primary care 
There is abundant evidence not only on the impairment and disability but also the reduced 
quality of life in GAD patients. Hospitalization and loss of productivity were the two major 
components of costs both in patients with and without comorbidity. Health care utilization 
rates were higher among those with comorbid GAD patients compared to pure GAD (Lieb 
et al., 2005). 
The burden of disability is clearly greater as the number of comorbidities increases 
(Wittchen et al., 2002; Kroenke et al., 2007; Löwe et al., 2008). Majority of pure GAD patients 
(66.7%) report impairment of occupational functioning, and selfreported disability days 
were 9.9 days in the preceding month. This was reported as 15.3 days for patients with pure 
MDE,  and 16.5 days for comorbid GAD and MDE (Witthchen et al., 2002). Kroenke et al. 
reported in their study that self-reported disability days of the patients with pure GAD 
during the previous 3 months were 18.1 days (Kroenke et al., 2007). A recent study 
comparing the functional impact of different anxiety disorders and their combinations 
showed that disability in GAD was significantly less present in comparison with other 
anxiety disorders. However, all measures of functioning and disability, except for physical 
functioning, showed substantial impairment in the overall sample when compared to 
general population. (Sherborne et al., 2010). ESEMed study found that GAD is associated 
with substantial level of disability as well as a decrease in the quality of life (Alonso et al., 
2004). Revicki et al. showed that anxiety symptoms of GAD patients in primary care settings 
were associated with impairments in generic health status, disability, disease-specific 
quality of life, and preference-based measures of health-related quality of life (Revicki et al., 
2008). In the WHO Primary Care study, 27% of the patients with GAD reported moderate or 
severe social disability, with a mean loss of 4.6 work days due to disability in the month 
preceding the assessment. When GAD was accompanied by major depression, the mean 
number of lost work days increased to 8.0 days (Lieb et al., 2005).  
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Presence of GAD, especially comorbidity with major depression, leads substantial 
impairment of social, professional, and family conditions rated by Sheehan disability scale 
(Wittchen & Hoyer, 2001; Ansseau et al., 2005; Olfson and Gameroff, 2007). The most serious 
effects of GAD were observed in the subscales for emotional role limitations and physical 
health role limitations (Stein, 2003). In a study where Medical Outcomes Study Short Form-
20 was used to determine functioning in GAD patients, all six domains of the scale were 
determined as impaired (Kroenke et al., 2007). 
Andlin-Sobocki and Wittchen reported total direct medical costs at €1958 and €3194 and 
indirect costs at €969 and €1659 for GAD and GAD with comorbidity, respectively (Andlin-
Sobocki and Wittchen, 2002). Olfson and Gameroff found that patients with GAD had a 
significantly higher median medical cost than patients without GAD ($2775 versus $1448), 
and patients with GAD and high pain interference had the highest mean predicted medical 
cost, $42.620. They also showed that GAD patients had a greater likelihood of making an 
emergency department visit (Olfson and Gameroff, 2007). 
5. Management of GAD in primary care 
The proper management of GAD in the primary care settings should not include only 
pharmacotherapy or psychotherapy but also education of patients and their families, 
counselling for lifestyle changes, as well as beneficial, continuous support, insomnia 
management, and development of coping strategies to manage their worries (Culpepper, 
2002). There is no evidence-based approach for the combination of different treatment 
options for GAD patients so there is a need for further researches including large study 
populations targeted on current practice (Allgulander, 2009). 
Education about GAD for both patients and their families must include its waxing and 
waning nature that can be managed by therapeutic interventions, compliance monitoring 
and feedback, and it should not reflect either moral weakness or character flaws leading to 
stigmatisation issue. Counseling; lifestyle changes like exercise, decreasing alcohol, caffeine, 
and tobacco consumption; regulating sleep; and controlling external stimuli for sleep 
improvement are encouraged. As insomnia, acute or chronic, is a norm among patients, 
PCPs have to understand and monitor its severity. Questions about “sleep hygiene”, use of 
alcohol, daytime sleepiness and problems in functioning can be helpful. Although patients 
often require short-term pharmacological therapy for their insomnia at the time of initial 
diagnosis (especially if insomnia is the presenting symptom), or at times of acute 
exacerbations, the priority of the physician should be helping patients to develop 
appropriate lifestyle changes that will promote its long-term control. GAD patients often 
find themselves rehashing problems and unmet expectations, especially during 
exacerbations, which they find hard to cope with. Simple anxiety coping techniques that 
help in gaining improved sense of self-control in times of crises can be taught (Culpepper, 
2002;Allgulander, 2009; Davidson et al., 2010). 
GAD patients deserve effective medical treatment with short and long-term goals. The 
short-term goals of treatment include reduction in somatic and psychic symptoms, and 
resolution of insomnia. Long-term goals should include achieving fully functional status 
that is affected by anxiety, preventing relapses or recurrences, and treatment of comorbid 
disorders GAD patients suffer from, such as depression. PCPs need to be aware of short and 
long-term adverse effects of their treatment like worsening of insomnia and agitation, and 
weight gain and sexual dysfunction, respectively (Culpepper, 2002).  
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Pharmacotherapy is the most common treatment option chosen by the physicians that needs 
to be emphasized as an extended treatment option. There are several treatment guidelines 
and a general consensus among these guidelines is that the first-line pharmacotherapy for 
GAD patients should include selective serotonin reuptake inhibitors (SSRIs) or serotonin-
norepinephrine reuptake inhibitors (SNRIs) (Katzman, 2009). The SSRIs such as paroxetine, 
first licensed SSRI for GAD, escitalopram; SNRIs such as venlafaxine, and duloxetine 
(recently approved in United States for GAD treatment) , buspirone, and benzodiazepins are 
commonly used agents in primary care (Katzman, 2009; Davidson et al., 2010). Tricyclic 
antidepressants and monoamine oxidase inhibitors should be reserved for patients not 
responding other regimens as they have potential for lethal overdose and serious adverse 
effects. Benzodiazepines are generally recommended for short-term use as they provide 
immediate relief of insomnia and somatic symptoms; however, those have less effect on 
psychological symptoms. Their long-term use causes problems of addiction and withdrawal 
leading conflicts with PCPs. Benzodiazepine use is also problematic for elderly due to the 
side effects like falling, memory impairment, and loss of coordination, drowsiness and 
confusion. PCPs have to be aware of adverse effects of these substances when used with 
other drugs like hypnotics, sedating antidepressants, opiate analgesics, anticonvulsants, anti 
histamines, and alcohol. (Culpepper, 2002; Davidson et al., 2010). Buspirone has 
disadvantages of delayed onset effect, short half-life , failure to treat comorbid anxiety or 
depressive disorders, and is generally less effective than the benzodiazepines, so it is not 
recommended as first-line treatment for GAD. Hydroxyzine, an antihistaminic, was also 
reported to be effective for GAD. Due to its sedating and anticholinergic effects, slow onset 
of action, and lack of efficacy for its comorbids, it is not preferred as first-line treatment 
(Davidson et al., 2010). SSRIs and an SNRI, venlafaxine are all equally efficient for treating 
GAD. When choosing between them, some parameters that need to be considered are cost 
and generic availability, the risk of breakthrough symptoms when a dose is missed, the ease 
of titration, the potential interaction with other drugs, and adverse effects. Venlafaxine, the 
first approved drug for GAD, is a valuable first-line treatment option for PCPs, indicated for 
long treatment of GAD, and also effective in comorbid depressive symptoms and 
depression. Its dosage should be titrated to minimise its adverse effects, such as nausea, 
dizziness, dry month, sleepiness. Patients should be monitored for a significant increase in 
blood pressure. Adverse effects include orthostatic hypotension, sweating, and urinary 
hesitancy (Culpepper, 2002; Davidson et al., 2010). Paroxetine has the disadvantages of long-
term weight gain, and withdrawal symptoms in case of dose omission. Evidence is 
emerging for atypical antipsychotics that they are effective in the treatment of patients with 
anxiety disorders both as monotherapy and augmentation to the standard treatment 
(Katzman, 2009; Davidson et al., 2010). 
There are different psychotherapy approaches and the most commonly used one is 
Cognitive-Behavioural Therapy (CBT). CBT includes psychoeducation, symptom 
management techniques, cognitive restructuring, exposure to anxiety producing events, 
relaxation training, and self-monitoring as important first-line treatment options in GAD 
with the advantage of patient preference and lack of adverse effects (Katzman, 2009). 
Although it was demonstrated that CBT is the most effective psychological treatment for 
GAD, clinical response for the treatment was found at less than 50% (Davidson et al., 2010). 
It is difficult to deliver the treatment adequately, as it needs extensive training of the 
therapist and time to take effect (van Boeijen et al., 2005). Although it is not possible for 
PCPs to provide CBT to their GAD patients they should act as guides in selection of 
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experienced CBT therapists, prescribe and monitor pharmacotherapy in coordination with 
the patient’s therapist, and help patients to use the therapeutic approaches of CBT following 
the conclusion of formal therapy, especially when they meet new stressors. Attempts have 
been made for CBT modifications such as ‘self-help’ approaches including ‘bibliotherapy’ 
(written format, self-help manuals), communication with peers, computerised systems, 
using a telephone and interactive voice response (Bower et al., 2001; van Boeijen et al., 
2005a, Allgulander, 2009). Bower et al. provided some preliminary evidence about self-help 
packages may offer some clinical advantages over routine primary care for anxiety and 
depressive disorders and van Boeijen et al. concluded that with more time spent on 
guidance on the use of the self-help manual, positive results can be achieved for even the 
patients with longstanding anxiety symptoms (Bower et al., 2001; van Boeijen et al., 2005a). 
It was shown in the study that the primary care patients with GAD may be treated by their 
GPs as effectively as after their referral to a psychiatric outpatient clinic, and self-help 
manual usage is easier for GPs than less structured guidelines resulting in fewer referrals to 
specialized care (van Boeijen et al., 2005b). Principles of CBT can also be useful while 
counselling with “high utilisers” and patients suffering acute exacerbations. PCPs can help 
patients identify and correct their misconceptions about events they perceive as worrying 
and automatic thought processes that underline the misconceptions, and to develop self-
regulation of these thoughts, feelings, and behaviours, namely cognitive restructuring 
(Culpepper, 2002). Another form of promising psychotherapy for GAD patients is the “well-
being therapy” (Davidson et al., 2010). 
A recent study published recommended a “unified approach” to the diagnosis, care 
management, and pharmacotherapy of primary care anxiety addressing the difficulty of 
assessing and managing multiple anxiety disorders in the primary care setting. The 
method emphasizes the identification of other medical or psychiatric comorbidities that 
can complicate the treatment, an approach for the initial education of the patient and 
discussion about treatment based on motivational interviewing, valid monitoring, an 
algorithmic approach for the selection of initial pharmacotherapy, and selection of 
alternative or adjunctive treatments (Roy-Byrne et al., 2009). This approach as a part of 
flexible treatment-delivery model, namely CALM (“Coordinated Anxiety Learning and 
Management”), was studied as a randomised controlled trial and compared with usual 
care in primary care settings. Roy-Byrne concluded that for patients with anxiety 
disorders treated by PCPs, a collaborative care resulted in greater improvement in 
managing anxiety symptoms and functional disability, and increasing quality of care over 
18 months (Roy-Byrne et al., 2010). 
6. Quality of care in primary care 
Young et al., defining poor-quality care as no care or inappropriate care in their study, 
showed that 80.5% of individuals visiting only PCPs had a poor-quality of care. Patients 
receiving poor-quality care from PCPs were less likely to report evaluation of mental 
health, recommendation of psychiatric medication, or referral to a mental health 
specialist. Patients not receiving appropriate care were most often most often from the 
following groups: men, black, older adults, young adults, people with only primary or no 
education, and people of lower socioeconomic status (Young et al., 2001). Stein et al. 
found that the level of appropriate care for anxiety disorders was moderate to low in 
patients that attended a university affiliated primary care practice. Nearly one third of the 
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patients had received counselling from their PCPs, with less than 10% receiving help from 
a mental health professional, including multiple elements of CBT. Approximately 40% of 
patients underwent appropriate pharmacotherapy in the preceding three months. 
However, only 25% received it at a minimally adequate dose and duration. Different 
studies determined different factors that had effects on receiving appropriate treatment. 
In one, the patients with comorbid depression and/or medical illnesses were more likely 
to receive appropriate treatment, while patients from ethnic minorities were less likely 
(Stein et al., 2004). Hyde et al., found that with greater severity of disease, measured by 
total score of GHQ-12, male patients had a significantly increased probability of receiving 
active treatment (Hyde et al, 2005). Weisberg et al. also emphasised in their study that 
racial/ethnic minority groups were less likely to be receiving treatments from 
psychiatrists (Weisberg et al., 2007). 
Young et al. discussed that there are many factors that can contribute to improper care and 
management of depressive and anxiety disorders. These include the perceived need, 
willingness for care, insurance coverage, and detection by physicians, and knowledge and 
beliefs of health care providers regarding effective treatment (Young et al., 2001). In a study 
carried out with a subsample of ESEMeD, the percentage of patients receiving adequate 
treatment in specialised and general medical care were 31.8% and 30.5%, respectively. In 
this study factors associated with appropriate treatment were living in a large city, a high 
education level, and a good self-rated health state (Fernándes et al., 2006). Weisberg et al. 
pointed out that primary care patient who were not receiving pharmacotherapy for their 
anxiety disorder claimed two main reasons for this. One was that their doctor never 
recommended treatment and the other was that they did not believe in medication for 
emotional problems. In the same study the most commonly claimed reasons for not 
receiving psychotherapy were patients’ lack of belief in psychotherapy, and their ignorance 
about the treatability of their emotional problems. Other barriers frequently mentioned for 
psychotherapy, but rarely for pharmacotherapy were cost, convenience, not knowing how 
to get into therapy (Weisberg et al., 2007). All of these seem to have a common base with 
barriers for accurate diagnosis. 
In a study searching for the cause and length of delays in care of specific subcategories of 
anxiety disorders, it was found that GAD patients seek help from their family physician or 
his/her equivalent 10.3 months after showing symptoms and visit an anxiety clinic for 83.8 
months after showing symptoms (Wagnet et al., 2006).  
7. Interventions for primary care 
It is obvious that problems encountered in diagnosis and management of GAD in PHC is 
multifaceted and multiphase and there is a need of integration of mental health in primary 
care. Primary care has the potential to reach the whole community as being the first point of 
contact and patient-centred interaction depending on long-lasting, trust based communication. 
This is also a support for the continuity of care, which is especially important for GAD patients 
having relapses and remissions. These advantages of primary care, along with all its handicaps 
can facilitate an integrated treatment approach (Rakel, 2007). 
In a systematic review evaluating the effectiveness of interventions aimed to improve 
recognition, diagnosis and management of patients with anxiety disorders, it was 
concluded that the most promising choice of care in general practice is a combination of 
professional interventions with organisational interventions, including an education 
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component where an external expert such as a nurse therapist or a psychologist is 
introduced (Heideman et al., 2005). 
A report prepared by WHO and WONCA (World Organization of Family Doctors) put 
forward the principles for the integration of mental health into primary care that are, 
naturally, appropriate for GAD. Some of these principles are supported in this paper, 
especially for GAD. These include: adequate training of primary care workers, limited and 
doable tasks for mental care, support to primary care by specialist mental health 
professionals and facilities, access to essential psychotropic medications in primary care, 
and collaboration of PCPs with other government non-health sectors, nongovernmental 
organizations (WHO&WONCA, 2008). 
8. Conclusions 
GAD is the most prevalent anxiety disorder in primary care. Its comorbidity is well-
documented, leading higher economic burden and a decrease in quality of life. Primary care 
settings are the best way of ensuring that GAD patients can get the care they need as they 
are accessible, affordable, acceptable, and cost-effective. Barriers for diagnosis and 
management of GAD in primary care include: nature of disease, patient- and physician-
related factors, and societal factors such as stigmatisation. The proper management of GAD 
is also multifaceted, and multistage, which means that PCPs needs appropriate counselling 
with guidelines and screening tools. Primary care is the place that can ensure patients 
achieve care in a holistic manner, addressing both their physical and mental health needs. 
Advantages of primary care have to be taken into account for quality improvement 
programs that will be implemented to enhance awareness and utilization of appropriate 
treatment options. 
9. Future research efforts 
 Researches accurately reflecting, and modelling the complexities of recognition in 
primary care 
 Models that increase patients’ and society’s awareness and physicians’ recognition of 
GAD 
 Effect of patients’ attribution styles on the physician’s recognition and recommendations 
needed to be studied for solutions to cope with the situation and achieving a more 
accurate diagnosis 
 Development of reliable and easy to use screening tools/instruments, and increased 
frequency of their use in primary care setting  
 Professional and organisational interventions for improvement of diagnosis and 
treatment of GAD need to be studied with a long-term follow up 
 Evidence to support the therapeutic value of combined treatments for more complex 
cases 
 Data showing the degree of unmet needs for treatment of GAD patients with economic 
burden, due to inappropriate treatment and inadequate inpatient and outpatient 
interventions 
 Studies that provide a chance to understand the reasons underlying low rates of quality 
care, and implementation of measures to improve them. 
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